Search research articles
Contact Us
Filters
Showing results (1-10 of 49) with videos related to
Page
of 5
Sort By:
The New England Journal of Medicine
|
December 4, 2014
Resistance to androgen-pathway drugs in prostate cancer
Julie Steinestel, Andres J Schrader, Manuel Luedeke
World Journal of Urology
|
March 1, 2017
Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems
Christof Bernemann, Julie Steinestel, Martin Boegemann, et al.
World Journal of Surgical Oncology
|
August 9, 2014
Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequences
Julie Steinestel, Sandra Steffens, Konrad Steinestel, et al.
Oncology Research and Treatment
|
April 3, 2017
[Not Available]
Christof Bernemann, Martin Bögemann, Julie Steinestel, et al.
Clinical and Translational Medicine
|
July 23, 2014
Clinical significance of epithelial-mesenchymal transition
Konrad Steinestel, Stefan Eder, Andres Jan Schrader, et al.
Oncotarget
|
April 27, 2017
Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness
Thomas J Schnoeller, Florian Jentzmik, Andres J Schrader, et al.
European Urology
|
September 20, 2016
Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
September 21, 2016
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
July 10, 2017
Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
Clinical Nuclear Medicine
|
February 23, 2026
Combined [223Ra]Radiumdichloride and [177Lu]Lu-PSMA-617 Therapy in End-stage Metastatic Castration-resistant Prostate Cancer
Martin J Hügle, Marianne Patt, Alexander Dierks, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 49) with videos related to
Sort By:
Page
of 5
The New England Journal of Medicine
|
December 4, 2014
Resistance to androgen-pathway drugs in prostate cancer
Julie Steinestel, Andres J Schrader, Manuel Luedeke
World Journal of Urology
|
March 1, 2017
Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems
Christof Bernemann, Julie Steinestel, Martin Boegemann, et al.
World Journal of Surgical Oncology
|
August 9, 2014
Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequences
Julie Steinestel, Sandra Steffens, Konrad Steinestel, et al.
Oncology Research and Treatment
|
April 3, 2017
[Not Available]
Christof Bernemann, Martin Bögemann, Julie Steinestel, et al.
Clinical and Translational Medicine
|
July 23, 2014
Clinical significance of epithelial-mesenchymal transition
Konrad Steinestel, Stefan Eder, Andres Jan Schrader, et al.
Oncotarget
|
April 27, 2017
Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness
Thomas J Schnoeller, Florian Jentzmik, Andres J Schrader, et al.
European Urology
|
September 20, 2016
Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
September 21, 2016
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
July 10, 2017
Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
Clinical Nuclear Medicine
|
February 23, 2026
Combined [223Ra]Radiumdichloride and [177Lu]Lu-PSMA-617 Therapy in End-stage Metastatic Castration-resistant Prostate Cancer
Martin J Hügle, Marianne Patt, Alexander Dierks, et al.
Page
of 5